Insulin Like Growth Factor-1 Against Oxidative Stress in Vitiligo

Launched by CAIRO UNIVERSITY · Mar 31, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a substance called Insulin Like Growth Factor-1 (IGF-1) on patients with vitiligo, a skin condition that causes loss of color in patches. Researchers believe that IGF-1 may help protect skin cells from damage caused by oxidative stress, which can worsen vitiligo. The trial will look at whether IGF-1 can help improve the condition in people who have non-segmental vitiligo, a common form of the disease.

To participate in this trial, you must be diagnosed with non-segmental vitiligo and be between the ages of 6 to 74. However, there are some important exclusions: if you are pregnant, smoke, have certain hormonal or liver diseases, are obese, or have a history of heart or blood vessel problems, you may not be eligible. The trial has not started recruiting participants yet, but if you qualify, you can expect to take part in research that could lead to new insights and potential treatments for vitiligo.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Non-segmental vitiligo
• Exclusion Criteria:
• • 1. Pregnant or lactating females
• • 2. Smokers
• • 3. Patients with any endocrinal disease known to affect GH or IGF-1 as Diabetes (by measuring HbA1c) and Thyroid disturbance (by measuring TSH)
• • 4. Patients with liver disease (by measuring AST, ALT and GGT)
• • 5. Obese patients (by measuring BMI)
• • 6. Patients with history of ischemic heart disease (known medical history of angina or myocardial infarction or history of recurrent chest pain, left shoulder pain, shortness of breath or fatigue on the ordinary effort or less than the ordinary effort )
• • 7. Patients with history of Peripheral arterial disease (Known medical history of peripheral arterial thrombosis or history of recurrent claudications)
• • 8. Patients with history of cerebero-vascular disease (known medical history of transient ischemic attacks or stroke)
• • 9. Patients who received systemic treatment for vitiligo during the previous six months or topical treatment during the previous two months